Fact sheet: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)

AIDSinfo

This fact sheet provides detailed information for patients about the combination antiretroviral drug Delstrigo.

September 11, 2018
Year of publication
2018
Resource types
Reports and Fact sheets
Tags
Delstrigo, combination antiretroviral therapy (cART)

Similar Resources

The Cochrane Library (ISSN 1465-1858) is a collection of six databases that contain different types of high-quality, independent evidence to inform healthcare decision-making, and a seventh database that provides information about Cochrane groups.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on vulnerable populations, including TB in prisons and intimate partner violence in the context of HIV.

This fact sheet provides detailed information for patients about the non-nucleoside reverse transcriptase inhibitor (NNRTI) Doravirine (Pifeltro).

Now that effective treatment for HIV is available, it is considered to be a long-term condition and many people are living long and healthy lives with HIV. This factsheet covers some key points about growing older with HIV.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on key populations.

In 2014, USAID/Tanzania awarded the Tanzania Strengthening Police and Prison Comprehensive HIV Services (SPPCHS) project as an initiative under the AIDSFree project.

The International Partnership for Microbicides (IPM) 2017 annual report takes a look at promising woman-centered technologies that could expand women's prevention options and help empower them to protect their sexual and reproductive health on their own terms.

This first volume of the 90-90-90 Compendium is targeted at a wide range of readers in South Africa, including community members and/or politicians with no medical background.

This first progress report shows that members of the Global HIV Prevention Coalition have mobilized around strengthening HIV primary prevention. There are clear signs of renewed political commitment and strengthened institutional arrangements for planning and managing prevention programmes.

In chronic HIV infection, initiation of antiretroviral therapy (ART) typically induces swift HIV RNA declines and virologic suppression within 24 weeks.